[Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
We have measured the plasma PIVKA-II levels in 188 cases of various liver disease with HCC and malignant diseases in other organs by an EIA, using a monoclonal antibody (E-1023 kit, Eisai), and also have measured the plasma vitamin K levels in cases of HCC and cholestasis by an HPLC. Plasma PIVKA-II was detected in many cases of HCC (67%, 35 of 52 cases) and cholestasis (60%, 6 of 10 cases). In contrast, the positivities of PIVKA-II in the other diseases including benign liver diseases were very low. Combination assays of PIVKA-II and vitamin K revealed that PIVKA-II correlates with vitamin K in cholestasis but not in HCC, suggesting that PIVKA-II in HCC does not depend on a systemic deficiency of vitamin K. From these results, it was concluded that PIVKA-II is a reliable marker which can reflect the clinical course of HCC.
Tada
H
H
3rd Dept. of Int. Med. Kyoto Prefectural Univ. of Med.
Kagawa
K
K
Hikita
H
H
Takeuchi
T
T
Ohta
Y
Y
Fukui
S
S
Shintani
H
H
Deguchi
T
T
Okanoue
T
T
Takino
T
T
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D014408:Biomarkers, Tumor / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000175:diagnosis* / Q000628:therapy; D002779:Cholestasis / Q000097:blood; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008107:Liver Diseases / Q000097:blood; D008113:Liver Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011498:Protein Precursors / Q000032:analysis* / Q000378:metabolism; D011516:Prothrombin / Q000032:analysis* / Q000378:metabolism; D014812:Vitamin K / Q000097:blood; D000509:alpha-Fetoproteins / Q000032:analysis
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D014408:Biomarkers, Tumor; D011498:Protein Precursors; D000509:alpha-Fetoproteins; D014812:Vitamin K; C008208:acarboxyprothrombin; D011516:Prothrombin